Drugs / CART-meso cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02580747 | Oct 2015 → Nov 2017 | endometrial cancer, malignant mesothelioma, malignant pancreatic neoplasm, ovarian neoplasm +1 | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03638193 | Jul 2018 → Feb 2022 | malignant pancreatic neoplasm | Shenzhen BinDeBio Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-meso cells | “Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-meso vector (referred to as CART-meso cells).” NCT02580747 ↗ |
| Action | Deplete | “may make the body build immune response to kill cancer cells.” NCT02580747 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cells transduced with the anti-meso vector (referred to as CART-meso cells)” NCT02580747 ↗ |
| Route | Intravenous | “A single dose of CART-meso T cells will be administered intravenously.” NCT03638193 ↗ |